pentobarbital will decrease the level or impact of elbasvir/grazoprevir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic outcome of elbasvir/grazoprevir could be lowered if coadministered with robust CYP3A inducers and it is for that reason contraindicated.pentobarbital will reduce the extent or outcome o